Results 181 to 190 of about 1,419,402 (298)

Building exteriors, Hebrew Orphan Asylum (Box 85, Folder 3) [PDF]

Digital ImageDigital finding ...
Hebrew Orphan Asylum of New York
core  

Labeling Pediatric Products: BPCA Efforts and Orphan Drug Opportunities. [PDF]

J Pediatr Pharmacol Ther
Wei H, Burckart GJ, Taylor-Zapata P, Wang Y.   +3 more
europepmc   +1 more source

The impact of the rare disease and Orphan Drug Act in Taiwan. [PDF]

J Food Drug Anal, 2021
Hsiang NC, Huang WF, Gau CS, Tsai TW, Chang LC.   +4 more
europepmc   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe [PDF]

An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 orphan diseases, only 50 orphan drugs (i.e. drugs developed to treat orphan diseases) were marketed in the EU by the end of 2008. In 2000, the EU implemented policies
Lut Mergaert, Christel Fostier, Steven Simoens, Alain Denis, Irina Cleemput   +4 more
core  

Predictive Analysis for First Submission of Generic Drug Application for Orphan Drug Products Using Random Survival Forest. [PDF]

Clin Transl Sci
Hopefl R, Wang J, Mohan AR, Sun WJ, Kim MJ, Hu M, Fang L.   +6 more
europepmc   +1 more source

Rare disease patients in India are rarely involved in international orphan drug trials. [PDF]

PLOS Glob Public Health, 2022
Chakraborty M, Choudhury MC, Chakraborty I, Saberwal G.   +3 more
europepmc   +1 more source

Ion binding sites and intermediate domain closure induced by D‐serine in the GluD1 ligand‐binding domain

The FEBS Journal, EarlyView.
GluD1 belongs to the ionotropic glutamate receptors and has important functions in the brain and brain diseases. We report the crystal structure of the GluD1 ligand‐binding domain with D‐serine and zinc ions. MD simulations supported promiscuous binding of cations and that chloride ions play a stabilizing role. Pro725 seems to hinder interlobe closure,
Flemming Steen Jørgensen, Emma Grosvald Pedersen, Dilip Narayanan, Karla A. Frydenvang, Jette Sandholm Kastrup   +4 more
wiley   +1 more source

Debates over orphan drug pricing: a meta-narrative literature review. [PDF]

Orphanet J Rare Dis
Hanchard MS.
europepmc   +1 more source

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study. [PDF]

Front Pharmacol, 2022
Gorini F, Santoro M, Pierini A, Mezzasalma L, Baldacci S, Bargagli E, Boncristiano A, Brunetto MR, Cameli P, Cappelli F, Castaman G, Coco B, Donati MA, Guerrini R, Linari S, Murro V, Olivotto I, Parronchi P, Pochiero F, Rossi O, Scappini B, Sodi A, Vannucchi AM, Coi A.   +23 more
europepmc   +1 more source